Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

ESC, EACPR urges MEPs to vote in favour of traffic light system for food labelling

The European Society of Cardiology http://www.escardio.org/ and its branch, the European Association for Cardiovascular Prevention and Rehabilitation http://www.escardio.org/communities/EACPR/Pages/welcome.aspx, are joining forces with 12 other European Health and consumer communities to urge MEPs to vote in favour of a traffic light system for food labelling today.

16 Jun 2010

European market for continuous glucose monitoring to reach $52M in 2016

The continuous glucose monitoring (CGM) market is in its development stage. The primary factor leading to the growth of the (CGM) market in Europe is the need for an easy-to-use and patient-friendly glucose-monitoring device. The traditional method of monitoring glucose was difficult and inconvenient for patients. The CGM method is not only hassle-free, but also gives a better diagnosis of diabetes.

16 Jun 2010

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

Sapient Discovery, LLC., a structure-guided drug discovery company, announced today that it has entered into a research collaboration agreement with the Helicon Therapeutics, Inc., a San Diego based pharmaceutical company. Under the terms of the agreement, Sapient Discovery will apply its proprietary structural biology platform and expertise to determine the three-dimensional structures for targets of interest to Helicon Therapeutics, Inc.

16 Jun 2010

Eating Mediterranean-style diet reduces heart disease risk: Research

A study of twins shows that even with genes that put them at higher risk of cardiovascular disease, eating a Mediterranean-style diet can improve heart function, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Peter and Patricia Gruber Foundation to present 2010 Neuroscience Prize to Robert H. Wurtz

Robert H. Wurtz, PhD, a pioneer and leader in the field of neurophysiology, is the recipient of the 2010 Neuroscience Prize of The Peter and Patricia Gruber Foundation. His discoveries of how the brain processes visual information and controls eye movements laid the groundwork for subsequent research into the neurophysiology of visual cognition. This research has led scientists to a deeper understanding of how the brain is organized to produce behavior.

15 Jun 2010

Study: Mentally active lifestyle may protect against memory and learning problems in MS

A new study shows that a mentally active lifestyle may protect against the memory and learning problems that often occur in multiple sclerosis. The study is published in the June 15, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

15 Jun 2010

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.

15 Jun 2010

First hospital in Mexico to use GORE HELEX Septal Occluder for transcatheter closure of ASD

W. L. Gore & Associates (Gore) today announced that Instituto Nacional De Cardiologia in Mexico City, Mexico, is the first hospital in the country to use the GORE® HELEX Septal Occluder for the transcatheter closure of an atrial septal defect (ASD). Department Chief, Dr. Carlos Zabal and Dr. Jose Garcia Montes of the Instituto Nacional de Cardiologia, in Mexico City, achieved the milestone procedure in March, 2010.

14 Jun 2010

CAMD releases first combined clinical trial data on neuro-degenerative diseases

A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials will be released today by the Coalition Against Major Diseases (CAMD). This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world.

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

First database of combined clinical trials on brain disease made available to qualified researchers

A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials was released today by the Coalition Against Major Diseases. This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world.

14 Jun 2010

Study results of genes regulated by ERB published in Journal of Biological Chemistry

Bionovo Inc. today announced the publication of results from a study demonstrating the three distinct classes of genes regulated by estrogen receptor beta. The results are published in the Journal of Biological Chemistry. This is an important discovery for future development of selective drugs regulating this pathway.

11 Jun 2010

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Data from the RE-NOVATE® II study presented today at the 15th Annual Congress of the European Hematology Association (EHA) have shown that dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery.

11 Jun 2010

NJIT biomedical engineer awarded $1.3M grant to develop better ways to help stroke patients

Helping stroke patients regain use of their hands and arms through innovative robotic and virtual reality-based video game therapies is the focal point of NJIT Associate Professor Sergei Adamovich, a biomedical engineer. Thanks to a $1.3 million grant from the National Institutes of Health, Adamovich is developing better ways to rehabilitate people who have lost control of their hands, fingers, shoulders and elbows.

11 Jun 2010

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.

11 Jun 2010

Neutralizing inhibitory molecules does not improve regeneration in damaged spinal axons

Neuroscientists at the University of California, San Diego School of Medicine have found that removing three key inhibitory molecules from myelin - the insulating material that surrounds nerve cell fibers - does not significantly boost the ability of injured spinal axons to regenerate and restore themselves to full function.

10 Jun 2010

2010 Independence Expo to promote active living and independence for aged and disabled Americans

United Spinal Association presents the 2010 Independence Expo – Long Island, the region's premier lifestyle-enhancing Expo designed to promote active living and independence for all people with disabilities and aging Americans.

10 Jun 2010

CPHA celebrates 12 great achievements of public health in Canada

The Canadian Public Health Association opens its doors this Sunday June, 13, 2010 to the public, introducing a walking tour of the 12 great achievements of public health in Canada. The 15,000 square foot CPHA Centenary EXPO titled This is Public Health features a dynamic display of visuals that highlights the importance of public health and its fundamental impact on the health of Canadians over the last 100 years.

10 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Stroke News and Research

Further Reading

ESC, EACPR urges MEPs to vote in favour of traffic light system for food labelling

European market for continuous glucose monitoring to reach $52M in 2016

Sapient Discovery, Helicon Therapeutics enter structural biology collaboration

Eating Mediterranean-style diet reduces heart disease risk: Research

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Peter and Patricia Gruber Foundation to present 2010 Neuroscience Prize to Robert H. Wurtz

Study: Mentally active lifestyle may protect against memory and learning problems in MS

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

First hospital in Mexico to use GORE HELEX Septal Occluder for transcatheter closure of ASD

CAMD releases first combined clinical trial data on neuro-degenerative diseases

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

First database of combined clinical trials on brain disease made available to qualified researchers

Study results of genes regulated by ERB published in Journal of Biological Chemistry

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

NJIT biomedical engineer awarded $1.3M grant to develop better ways to help stroke patients

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Neutralizing inhibitory molecules does not improve regeneration in damaged spinal axons

2010 Independence Expo to promote active living and independence for aged and disabled Americans

CPHA celebrates 12 great achievements of public health in Canada

Caregiver's guide on avoiding life-threatening swallowing problems

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News